&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-08, 13:35

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-06-07, 15:30

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-02-26, 14:05

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Cassie Shields

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-04-13, 12:15

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

Popular Posts